KONFUMIN

ANTIHYPOXIC DRUG, ANTIOXIDANT, VOLUME CORRECTOR — GIVES THE TIME

Konfumin® was developed at the FSBI Russian Research Institute of Hematology and Transfusiology under Federal Medical and Biological Agency of Russia in 2002. It is a 15% sodium fumarate solution for intravenous infusions. Presentation: plastic containers of 50 and 100 ml capacity.

A large group of humoral factors resulting in "hidden blood loss", are known as a group of vasotoxins. Among the latter, cytokines play a significant role (3). It's common knowledge that tumour necrosis factor and proinflammatory cytokines, particularly interleukin-1, are synthesised as a result of organ and tissue reperfusion [4,5]. Cytokine storm activation induces microthrombi formation, impairs vascular permeability, leads to interstitial oedema, vasodilation of peripheral vessels and uncontrolled arterial hypotension [5,6].

Konfumin® has a pronounced antihypoxic effect. Sodium fumarate activates adaptation of the cells to oxygen deficiency due to participation in reversible oxidation-reduction reactions in the Krebs cycle. ATP synthesis in the quantity sufficient to maintain body cell functions in hypoxia, occurs during these reactions.

Konfumin® is a hypertonic sodium fumarate solution. Its infusion into the bloodstream results in a volaemic effect. In contrast to hypertonic sodium chloride solutions, it does not intensify metabolic acidosis.

Konfumin® helps to reduce the concentration of lipid peroxidation products in the blood suggesting its antioxidant properties.

Konfumin® is compatible with all the known infusion therapy agents. It is administered by intravenous drip (20-30 drops per minute) at a dose of 100 ml. The dosing interval should be at least 6 hours. Maximum daily dose is 300 ml.